ClinicalTrials.gg
TerminatedNCT00697697Updated Jan 9, 2014Results posted

A Study of 2 Doses of MAP0010 in Asthmatic Children

A Phase 3 interventional study of 0.135mg MAP0010 and 0.25mg MAP0010 in Asthma, sponsored by Allergan. Terminated. Open to participants aged 12 Months to 8 Years. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Why this study was terminated
Corporate decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
12 Months to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
48th of 108
192 · median 124
Started
2008
with 6 others
Phase 3
51 of 110
3 open now
Registered
55th of 110
by date
Lead sponsor
5 of 110
Allergan

Among the 110 studies testing budesonide in Asthma, this one is the 48th largest by enrollment of the 108 interventional ones that give a count, is one of 7 that started in 2008, is one of 51 in phase 3, and was the 55th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Months to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthmatic children
04

Who can participate

Ages eligible
12 Months to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed 12 weeks of treatment in the MAP0010-CL-P301 study.
  • Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the and assent, as appropriate.

Exclusion criteria

Exclusion Criteria:

  • Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom e-diary) in the MAP0010-CL-P301 Study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    0.135mg MAP0010

    0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

    Drug: 0.135mg MAP0010

  • Experimental
    0.25mg MAP0010

    0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

    Drug: 0.25mg MAP0010

Interventions

  • 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

  • 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

06

What researchers measure

Primary outcomes

  1. Number of Patients With Treatment Emergent Adverse Events Related to Study Drug

    A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.

    Time frame: 40 weeks

  2. Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination

    A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.

    Time frame: 40 weeks

07

Results

Posted Oct 23, 2013
Limitations and caveats
The study was terminated due to a corporate decision before all subjects had completed the study.

Participant flow

Participant flow — Overall Study
Milestone0.135mg MAP00100.25mg MAP0010
Started9498
Completed4544
Not completed4954

Outcome measures

PrimaryNumber of Patients With Treatment Emergent Adverse Events Related to Study Drug

A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.

Time frame:
40 weeks
Reported as:
Number · participants
Number of Patients With Treatment Emergent Adverse Events Related to Study Drug
participants0.135mg MAP00100.25mg MAP0010
Number of Patients With Treatment Emergent Adverse Events Related to Study Drug64
PrimaryNumber of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination

A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.

Time frame:
40 weeks
Reported as:
Number · participants
Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination
participants0.135mg MAP00100.25mg MAP0010
Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination87

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.135mg MAP0010—0/94 (0%)71/94 (75.5%)
0.25mg MAP0010—1/98 (1%)85/98 (86.7%)
Most frequent serious events
Most frequent serious events
Event0.135mg MAP00100.25mg MAP0010
Acquired hydroceleReproductive system and breast disorders0/941/98
Most frequent other events
Showing 10 of 13
Most frequent other events
Event0.135mg MAP00100.25mg MAP0010
Upper Respiratory Tract InfectionInfections and infestations17/9432/98
AsthmaRespiratory, thoracic and mediastinal disorders19/9412/98
PyrexiaGeneral disorders4/9412/98
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders3/9411/98
Pharyngitis streptococcalInfections and infestations10/945/98
SinusitisInfections and infestations7/942/98
PharyngitisInfections and infestations2/946/98
CoughRespiratory, thoracic and mediastinal disorders4/946/98
NasopharyngitisInfections and infestations5/944/98
RhinitisInfections and infestations2/945/98

Baseline characteristics

Subjects were randomly assigned to treatment.

Age, Continuous
Age, Continuous(years)0.135mg MAP00100.25mg MAP0010Total
Mean4.6 ± 2.504.9 ± 2.034.8 ± 2.27
Age, Continuous
Age, Continuous(years)0.135mg MAP00100.25mg MAP0010Total
Median5.0 (1 to 9)5.0 (1 to 8)5.0 (1 to 9)
Sex: Female, Male
Sex: Female, Male(Participants)0.135mg MAP00100.25mg MAP0010Total
Female463783
Male4861109
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Aug 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 16, 2008
Start
Apr 2008
Primary completionActual
Aug 2009
CompletionActual
Dec 2009
Results first posted
Oct 23, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00697697
Lead sponsor
Allergan
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Responsible party
Sponsor
First posted
Jun 16, 2008
Start date
Apr 2008
Primary completion
Aug 2009
Completion
Dec 2009
Results posted
Oct 23, 2013
Last update
Jan 9, 2014

Study contacts

Medical Director
study director · MAP Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion